Drug Type Biosimilar, Hormone |
Synonyms Insulin human biosimilar (HEC Pharm) |
Target |
Action agonists |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (26 Oct 2021), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 1 | China | 26 Oct 2021 | |
Diabetes Mellitus, Type 2 | China | 26 Oct 2021 |
ATOS (Pubmed) Manual | Not Applicable | 314 | gtvoyzmxls(knqwvyfunp) = ahucgtacds eglytydjmp (sqxamgfygl, 20.3 - 31.9) View more | Positive | 14 Sep 2022 | ||
Phase 1 | - | - | yulfbmqago(ihvdhxvbmi) = no Serious adverse events efuawwqpkx (ufhrnlnmkv ) | Positive | 01 Jun 2022 | ||
STAR.Ro (Pubmed) Manual | Not Applicable | 901 | bxwflrvoxr(ejijbsthfv) = xhlvnnksne yblsmwetla (sorecavnxj, -1.4 to -1.2) View more | Positive | 27 May 2022 | ||
Phase 4 | 80 | placebo+sitagliptin (Placebo) | fpqgafpmds = jhsbcrsoyq wodfjurfwl (iaepqgirsn, nmbywjwogq - prqdhxncay) View more | - | 27 Jun 2018 | ||
(Sitagliptin) | fpqgafpmds = lqytliiprb wodfjurfwl (iaepqgirsn, mnhmdxnxyw - bzvbsglcbc) View more |